Sepsis market Strong focus on molecular diagnostics for sepsis with SeptiCyte products, offering a defensible clinical value proposition to hospitals and critical care networks seeking improved sepsis detection and triage.

Clinical evidence Recent engagement at SCCM 2026 and high correlation data between SeptiCyte RAPID and blood culture positives provide opportunities to leverage key clinical outcomes and payer discussions for adoption.

Global footprint Operations in Seattle and Brisbane suggest potential for multinational hospital deployments, international reimbursement negotiations, and cross-border partnership opportunities in North America and Australia/Asia-Pacific.

Growth levers Recent product launches and cartridge expansions for EDTA compatibility indicate scalability and broader market access, enabling upgrades or swaps in existing sepsis testing workflows.

Strategic partnerships Past collaborations with Biocartis and BARDA grant support present a track record for co-development and grant-backed funding, highlighting avenues for co-marketing, embedded solutions, and government or large health-system programs.